TY - JOUR
T1 - Intraoperative radioimmunolocalization of an anti-CEA MAb F(Ab′)2 (FO23C5) in CEA serum-negative colorectal cancer patients
AU - Roselli, Mario
AU - Guadagni, Fiorella
AU - Buonomo, Oreste
AU - Belardi, Augusto
AU - Vittorini, Vincenzo
AU - Cavazzana, Andrea
AU - Spagnoli, Luigi Giusto
AU - Cipriani, Cesidio
AU - Casciani, Carlo Umberto
PY - 1996
Y1 - 1996
N2 - Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery™ (RIGS®) with an anti-CEA F023C5 F(Ab′)2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.
AB - Serum positivity to an antigen recognized by the monoclonal antibody (MAb) which will be administered is frequently being used as a predictive criterion for positive MAb tumor localization. In the present study, which is based on our previous data that clearly showed no correlation between quantitative levels of CEA in sera and in carcinoma tissues, we selected a population of 12 primary colorectal carcinoma patients which were serum CEA-negative. The main purpose was to assess the potential diagnostic use of Radioimmunoguided Surgery™ (RIGS®) with an anti-CEA F023C5 F(Ab′)2 MAb and its clinical value in this series of patients. In all RIGS patients, the MAb localized to histologically confirmed tumor; this included 96% of primary tumor tissues, 29% of lymph nodes and one occult liver metastasis. Thus, serum CEA positivity should not be a criterion for the use of anti-CEA MAbs for the diagnosis of colon cancer, since the serum CEA level is not indicative of CEA expression in tumors.
KW - I-FO23C5
KW - Anti-CEA MAb
KW - Carcinoembryonic antigen
KW - Colorectal cancer
KW - Radioimmunoguided surgery
UR - http://www.scopus.com/inward/record.url?scp=0029898693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0029898693&partnerID=8YFLogxK
M3 - Article
C2 - 8687145
AN - SCOPUS:0029898693
VL - 16
SP - 883
EP - 890
JO - Anticancer Research
JF - Anticancer Research
SN - 0250-7005
IS - 2
ER -